{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:03:07Z","timestamp":1787320987091,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100016958","name":"Office of Research Infrastructure Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51 OD011132"],"award-info":[{"award-number":["P51 OD011132"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijmmb.2025.100940","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:50:38Z","timestamp":1753141838000},"page":"100940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of HCV vaccine: Where do we stand?"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-9155","authenticated-orcid":false,"given":"Pachamuthu","family":"Balakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmugam","family":"Saravanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5805-9169","authenticated-orcid":false,"given":"Ramachandran","family":"Vignesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathasivam","family":"Sivamalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duraisamy","family":"Nallusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-5231","authenticated-orcid":false,"given":"Sathish","family":"Sankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekaran","family":"Krithika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitathoor","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivadoss","family":"Raju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayakumar","family":"Velu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esaki M.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib1","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.ijmmb.2025.100940_bib2","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Global Health"},{"issue":"7350","key":"10.1016\/j.ijmmb.2025.100940_bib3","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/474S2a","article-title":"Introduction: a smouldering public-health crisis","volume":"474","author":"Gravitz","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ijmmb.2025.100940_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJMoa2023345","article-title":"Randomized trial of a vaccine regimen to prevent chronic HCV infection","volume":"384","author":"Page","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib6","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/v15051151","article-title":"Current hepatitis C vaccine candidates based on the induction of neutralizing antibodies","volume":"15","author":"Gomez-Escobar","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/vaccines8010090","article-title":"Hepatitis C virus vaccine: challenges and prospects","volume":"8","author":"Duncan","year":"2020","journal-title":"Vaccines"},{"issue":"8","key":"10.1016\/j.ijmmb.2025.100940_bib8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.3390\/v16081337","article-title":"Update on hepatitis C vaccine: results and challenges","volume":"16","author":"Garbuglia","year":"2024","journal-title":"Viruses"},{"issue":"38","key":"10.1016\/j.ijmmb.2025.100940_bib9","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib10","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"J Viral Hepat"},{"issue":"10","key":"10.1016\/j.ijmmb.2025.100940_bib11","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006\u20132012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ijmmb.2025.100940_bib12","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/infdis\/jiaa006","article-title":"Prevalence and phylogenetic characterization of hepatitis C virus among Indian men who have sex with men: limited evidence for sexual transmission","volume":"221","author":"Clipman","year":"2020","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.ijmmb.2025.100940_bib13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/hep.31912","article-title":"Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India","volume":"74","author":"Clipman","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib14","article-title":"Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals","volume":"4","author":"Howe","year":"2022","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.gastro.2009.09.017","article-title":"Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection","volume":"138","author":"Osburn","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147879","article-title":"Burden of liver disease among community-based people who inject drugs (PWID) in chennai, India","volume":"11","author":"Solomon","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1473-3099(12)70010-5","article-title":"Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine","volume":"12","author":"Grebely","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.ijmmb.2025.100940_bib19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2018.08.060","article-title":"Approaches, progress, and challenges to hepatitis C vaccine development","volume":"156","author":"Bailey","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijmmb.2025.100940_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/473909","article-title":"Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients","volume":"2015","author":"Yutani","year":"2015","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3390\/v15051109","article-title":"Virus-like particle vaccines and platforms for vaccine development","volume":"15","author":"Kheirvari","year":"2023","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.ijmmb.2025.100940_bib22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.20934","article-title":"Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee","volume":"42","author":"Youn","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ijmmb.2025.100940_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4161\/hv.5.3.6614","article-title":"Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIXTM vaccine: a phase I study in healthy volunteers","volume":"5","author":"Drane","year":"2009","journal-title":"Hum Vaccines"},{"issue":"7","key":"10.1016\/j.ijmmb.2025.100940_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/vaccines9070761","article-title":"Combating human viral diseases: will plant-based vaccines Be the answer?","volume":"9","author":"Venkataraman","year":"2021","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.ijmmb.2025.100940_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1053\/jhep.2001.26523","article-title":"Hepatitis C virus-like particles induce virus\u2013specific humoral and cellular immune responses in mice","volume":"34","author":"Lechmann","year":"2001","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.ijmmb.2025.100940_bib43","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/mt.2013.119","article-title":"Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C","volume":"21","author":"Weiland","year":"2013","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ijmmb.2025.100940_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","article-title":"Immunogenicity of CIGB\u2010230, a therapeutic DNA vaccine preparation, in HCV\u2010chronically infected individuals in a phase I clinical trial","volume":"16","author":"Alvarez\u2010Lajonchere","year":"2009","journal-title":"J Viral Hepat"},{"issue":"23\u201324","key":"10.1016\/j.ijmmb.2025.100940_bib25","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers","volume":"22","author":"Leroux-Roels","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.ijmmb.2025.100940_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1158\/1940-6207.CAPR-22-0217","article-title":"Phase I trial of a therapeutic DNA vaccine for preventing hepatocellular carcinoma from chronic hepatitis C virus (HCV) infection","volume":"16","author":"Jacobson","year":"2023","journal-title":"Cancer Prev Res (Phila Pa)"},{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2020.02.009","article-title":"IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses","volume":"73","author":"Han","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ijmmb.2025.100940_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2011.06.009","article-title":"A poxvirus vaccine is safe, induces T-Cell responses, and decreases viral load in patients with chronic hepatitis C","volume":"141","author":"Habersetzer","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.ijmmb.2025.100940_bib30","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MEG.0000000000000084","article-title":"VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection","volume":"26","author":"Di Bisceglie","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"23","key":"10.1016\/j.ijmmb.2025.100940_bib31","doi-asserted-by":"crossref","first-page":"10486","DOI":"10.1128\/JVI.01462-16","article-title":"Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice","volume":"90","author":"Li","year":"2016","journal-title":"J Virol"},{"issue":"20","key":"10.1016\/j.ijmmb.2025.100940_bib34","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10.1016\/j.ijmmb.2025.100940_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JVI.78.1.187-196.2004","article-title":"Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-Helper immune response","volume":"78","author":"Rollier","year":"2004","journal-title":"J Virol"},{"issue":"548","key":"10.1016\/j.ijmmb.2025.100940_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7715","article-title":"MHC class II invariant chain\u2013adjuvanted viral vectored vaccines enhances T cell responses in humans","volume":"12","author":"Esposito","year":"2020","journal-title":"Sci Transl Med"},{"issue":"261","key":"10.1016\/j.ijmmb.2025.100940_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-Specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"115","key":"10.1016\/j.ijmmb.2025.100940_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijmmb.2025.100940_bib39","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ijmmb.2025.100940_bib42","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1053\/j.gastro.2008.02.058","article-title":"Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41","volume":"134","author":"Klade","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijmmb.2025.100940_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.576572","article-title":"Technical validation of a hepatitis C virus whole genome sequencing assay for detection of genotype and antiviral resistance in the clinical pathway","volume":"11","author":"Manso","year":"2020","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.ijmmb.2025.100940_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.ijmmb.2025.100940_bib20","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036947","article-title":"Challenges and promise of a hepatitis C virus vaccine","volume":"10","author":"Cox","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"10.1016\/j.ijmmb.2025.100940_bib46","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/v13081596","article-title":"Hepatitis C virus vaccine research: time to put up or shut up","volume":"13","author":"Hartlage","year":"2021","journal-title":"Viruses"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085725001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085725001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:40:31Z","timestamp":1772754031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085725001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S0255085725001537"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2025.100940","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of HCV vaccine: Where do we stand?","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2025.100940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100940"}}